Posted inCardiology Diabetes & Endocrinology news
Evolocumab Prevents First Major Cardiovascular Events in High‑Risk Patients without Prior MI or Stroke
In VESALIUS-CV, evolocumab reduced first major adverse cardiovascular events by ~25% (HR 0.75) versus placebo in patients with atherosclerosis or diabetes without prior myocardial infarction or stroke, with modest absolute risk reductions and no new safety signals over 4.6 years.
